BaileyR, CalhounP, GargSK. Weight gain and glycemic control in adults with type 1 diabetes in the T1D exchange registry. Diabetes Technol Ther, 2024; 26(3):156–160; doi: 10.1089/dia.2023.0389
3.
NathanDM, GenuthS, LachinJ, et al.; Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus. N Engl J Med, 1993; 329(14):977–986; doi: 10.1056/NEJM199309303291401
BattelinoT, AlexanderCM, AmielSA, et al.Continuous glucose monitoring and metrics for clinical trials: An international consensus statement. Lancet Diabetes Endocrinol, 2023; 11(1):42–57; doi: 10.1016/S2213-8587(22)00319-9
6.
GargSK. Past, present, and future of continuous glucose monitors. Diabetes Technol Ther, 2023; 25(S3):S1–S4; doi: 10.1089/dia.2023.0041
7.
GargS, KipnesMS, CastorinoK, et al.Accuracy and safety of Dexcom G7 continuous glucose monitoring in adults with diabetes. Diabetes Technol Ther, 2022; 24(6):373–380; doi: 10.1089/dia.2022.0011
8.
BattelinoT, DanneT, BergenstalRM, et al.Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the international consensus on time in range. Diabetes Care, 2019; 42(8):1593–1603.
9.
El MalahiA, Van ElsenM, CharleerS, et al.Relationship between time in range, glycemic variability, HbA1c, and complications in adults with type 1 diabetes mellitus. J Clin Endocrinol Metab, 2022; 107(2):e570–e581; doi: 10.1210/clinem/dgab688
10.
GargSK, HirschIB, RepettoE, et al.Impact of continuous glucose monitoring on hospitalizations and glucose control in people with type 2 diabetes: Real-world analysis. Diabetes Obes Metab, 2024; 26(11):5202–5210; doi: 10.1111/dom.15866
11.
GargSK, McVeanJJ. Development and future of automated insulin delivery (AID) systems. Diabetes Technol Ther, 2024; 26(S3):1–6; doi: 10.1089/dia.2023.0467
12.
SabooB, GargS, BergenstalRM, et al.; Call-to-Action Coalition. A call-to-action to eliminate barriers to accessing automated insulin delivery systems for people with type 1 diabetes. Diabetes Technol Ther, 2025; 27(3):147–151; doi: 10.1089/dia.2025.0028
13.
VirdiN, PoonY, AbanielR, BergenstalRM. Prevalence, cost, and burden of diabetic ketoacidosis. Diabetes Technol Ther, 2023; 25(S3):S75–S84; doi: 10.1089/dia.2023.0149
14.
EledrisiMS, ElzoukiAN. Management of diabetic ketoacidosis in adults: A narrative review. Saudi J Med Med Sci, 2020; 8(3):165–173; doi: 10.4103/sjmms.sjmms_478_19
15.
GargSK, PetersAL, BuseJB, et al.Strategy for mitigating DKA risk in patients with type 1 diabetes on adjunctive treatment with SGLT inhibitors: A STICH protocol. Diabetes Technol Ther, 2018; 20(9):571–575; doi: 10.1089/dia.2018.0246
16.
RodbardD. Continuous glucose monitoring: A review of recent studies demonstrating improved glycemic outcomes. Diabetes Technol Ther, 2017; 19(S3):S25–S37; doi: 10.1089/dia.2017.0035
17.
GargSK, HenryRR, BanksP, et al.Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med, 2017; 377(24):2337–2348.
18.
GargSK, Snell-BergeonJ, KaurG, BeatsonC. Challenges of GLP analog use for people with type 1 diabetes: Issues with prior approvals and tips for safer use. Diabetes Technol Ther, 2024; 26(6):363–366; doi: 10.1089/dia.2024.0023
19.
Snell-BergeonJK, KaurG, RennerD, et al.Effectiveness of semaglutide and tirzepatide in overweight and obese adults with type 1 diabetes. Diabetes Technol Ther, 2025; 27(1):1–9; doi: 10.1089/dia.2024.0328
20.
GargSK, KaurG, RennerD, et al.Cardiovascular and renal biomarkers in overweight and obese adults with type 1 diabetes treated with tirzepatide for 21 months. Diabetes Technol Ther, 2025; 27(3):152–160; doi: 10.1089/dia.2024.0481
21.
GosmanovAR, GosmanovaEO, KitabchiAE. Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State. [Updated 2021 May 9]. In: (FeingoldKR, AhmedSF, AnawaltB, et al. eds). Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279052/#
22.
ChowE, ClementS, GargR. Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors. BMJ Open Diabetes Res Care, 2023; 11(5):e003666; doi: 10.1136/bmjdrc-2023-003666
23.
MohanV, LeeK. Global Burden of Diabetic Ketoacidosis. Diabetes Technol Ther. 2025; 27(4S):S6–S13; doi: 10.1177/15209156251390828
24.
RamphulK, JoynauthJ. An update on the incidence and burden of diabetic ketoacidosis in the U.S. Diabetes Care, 2020; 43(12):e196–e197; doi: 10.2337/dc20-1258
25.
UmpierrezGE, DavisGM, ElSayedNA, et al.Hyperglycaemic crises in adults with diabetes: A consensus report. Diabetologia, 2024; 67(8):1455–1479; doi: 10.1007/s00125-024-06183-8
26.
PanjwaniQ, BindalA. Economic impact of Diabetic Ketoacidosis (DKA) in the U.S. Diabetes Technol Ther, 2025; 27(4S):S14–S19; doi: 10.1177/15209156251390832
27.
Albanese-O’NeillA, WuM, MillerKM, et al.; T1D Exchange Clinic Network. Poor adherence to ketone testing in patients with type 1 diabetes. Diabetes Care, 2017; 40(4):e38–e39; doi: 10.2337/dc16-2620
28.
FosterNC, BeckRW, MillerKM, et al.State of type 1 Diabetes management and outcomes from the T1D exchange in 2016–2018. Diabetes Technol Ther, 2019; 21(2):66–72.
29.
AlvaS, CastorinoK, ChoH, OuJ. Feasibility of continuous ketone monitoring in subcutaneous tissue using a ketone sensor. J Diabetes Sci Technol, 2021; 15(4):768–774; doi: 10.1177/19322968211008185
Foti RandazzeseS, La RoccaM, BombaciB, et al.Severe diabetic ketoacidosis in children with type 1 diabetes: Ongoing challenges in care. Children (Basel), 2025; 12(1):110; doi: 10.3390/children12010110
34.
Usher-SmithJA, ThompsonM, ErcoleA, WalterFM. Variation between countries in the frequency of diabetic ketoacidosis at first presentation of type 1 diabetes in children: A systematic review. Diabetologia, 2012; 55(11):2878–2894; doi: 10.1007/s00125-012-2690-2
35.
HammersenJ, TittelSR, WarnckeK, et al.; DPV Initiative. Previous diabetic ketoacidosis as a risk factor for recurrence in a large prospective contemporary pediatric cohort: Results from the DPV initiative. Pediatr Diabetes, 2021; 22(3):455–462; doi: 10.1111/pedi.13185
36.
GibbFW, TeohWL, GrahamJ, LockmanKA. Risk of death following admission to a UK hospital with diabetic ketoacidosis. Diabetologia, 2016; 59(10):2082–2087; doi: 10.1007/s00125-016-4034-0
37.
InselRA, DunneJL, AtkinsonMA, et al.Staging presymptomatic type 1 diabetes: A scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care, 2015; 38(10):1964–1974.
38.
SherrJL, CobryEC. The future of dual glucose-ketone monitoring in youth with diabetes. Diabetes Technol Ther, 2025; 27(4S):S36–S43; doi: 10.1177/15209156251370944
39.
DandonaP, MathieuC, PhillipM, et al.; DEPICT-1 Investigators. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: The DEPICT-1 52-week study. Diabetes Care, 2018; 41(12):2552–2559.
40.
RosenstockJ, MarquardJ, LaffelLM, et al.Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: The EASE Trials. Diabetes Care, 2018; 41(12):2560–2569.
41.
BuseJB, GargSK, RosenstockJ, et al.Fifty-two-week efficacy and safety of sotagliflozin, a dual SGLT and SGLT2 inhibitor, as adjunct therapy to insulin in adults with type 1 diabetes (inTandem1). Diabetes Care, 2018; 67(Supplement_1); doi: 10.2337/db18-212-OR
AkturkHK, PerkinsBA, DunnTC. Clinical trials in diabetes: Examining the value of use of continuous glucose-ketone monitoring. Diabetes Technol Ther, 2025; 27(4S):S44–S50; doi: 10.1177/15209156251390818
